I. Marimón

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

J. Baselga, F. Rojo, J. Albanell, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fate of plasma glucose in tissues of brown trout in vivo: effects of fasting and glucose loading

I. Marimón, J. Blasco, J. Fernández-Borrás, 2001, Fish Physiology and Biochemistry.

Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing.

G. Grasselli, I. Marimón, C. Sessa, 2006, European journal of cancer.

Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer

Susan Quinn, Gunnar Folprecht, Josep Tabernero, 2008, Clinical Cancer Research.

Plasma glucose kinetics and tissue uptake in brown trout in vivo: effect of an intravascular glucose load

I. Marimón, A. Requena, J. Blasco, 2004, Journal of Comparative Physiology B.

Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.

J. Baselga, E. Felip, J. Albanell, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Feasibility of CT scan-guided Tru-Cut serial liver biopsies to evaluate pharmacodynamic endpoints in patients with liver metastasis treated with experimental drugs

J. Baselga, I. Marimón, J. Tabernero, 2004, Abdominal Imaging.